RMG-1

RMGI（RMG-1）/RMGI（RMG-1）细胞系/RMGI（RMG-1）细胞株/RMGI（RMG-1）卵巢癌细胞

Cell line name RMG-I

Synonyms RMGI; RMG1; RMG-1

Accession CVCL_1662

Resource Identification Initiative To cite this cell line use: RMG-I (RRID:CVCL_1662)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Population: Japanese.

Doubling time: 60 hours (PubMed=3154025); 40 hours (PubMed=25984343); ~3 days (Note=Lot 07022008), ~72 hours (Note=Lot 12252012), ~57 hours (Note=Lot 01212019) (JCRB=IFO50315); ~30 hours (Note=Lot 07052011), ~31 hours (Note=Lot 07142017), ~33 hours (Note=Lot 02042020) (JCRB=JCRB0172).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Genome sequenced.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.

Sequence variations

Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=8980248).

Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Arg (c.174A>C) (p.Ser73Arg, c.217A>C); ClinVar=VCV000128200; Zygosity=Unspecified (PubMed=25846456).

Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).

Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP=909699; DepMap=ACH-000719).

HLA typing Source: PubMed=25960936

Class I

HLA-A A*24:02,24:02

HLA-B B*40:02,40:02

HLA-C C*03:04,03:04

 

Source: PubMed=26589293

Class I

HLA-A A*24:02,24:02

HLA-B B*40:02,40:02

HLA-C C*03:04,03:04

Class II

HLA-DR DRB1*11:02,11:02

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 0

Native American 0.61

East Asian, North 81.67

East Asian, South 17.3

South Asian 0

European, North 0.42

European, South 0

Disease Ovarian clear cell adenocarcinoma (NCIt: C40078)

Clear cell adenocarcinoma of the ovary (ORDO: Orphanet_398971)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_IS64 (RMG-I-C) CVCL_IS65 (RMG-I-H)

Sex of cell Female

Age at sampling 34Y

Category Cancer cell line

STR profile Source(s): Cosmic-CLP=909699; JCRB=IFO50315; JCRB=JCRB0172; PubMed=25877200; PubMed=30485824

 

Markers:

Amelogenin X

CSF1PO 10

D3S1358 15,16

D5S818 12

D7S820 11

D8S1179 15,16

D13S317 8,12

D16S539 9,10

D18S51 13,15

D21S11 29,30

FGA 25,26

Penta D 9,10

Penta E 15,16

TH01 6,7

TPOX 11

vWA 17,18

 

PubMed=3154025

Nozawa S., Tsukazaki K., Sakayori M., Jeng C.-H., Iizuka R.

Establishment of a human ovarian clear cell carcinoma cell line (RMG-I) and its single cell cloning -- with special reference to the stem cell of the tumor.

Hum. Cell 1:426-435(1988)

 

PubMed=8980248; DOI=10.1002/(SICI)1097-0215(19961220)69:6<466::AID-IJC8>3.0.CO;2-2

Ichikawa Y., Yoshida S., Koyama Y., Hirai M., Ishikawa T., Nishida M., Tsunoda H., Kubo T., Miwa M., Uchida K.

Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors.

Int. J. Cancer 69:466-470(1996)

 

CLPUB00481

Kuno H., Yoshida T.

Detection of human papillomavirus types 16, 18, and 33 in cell lines derived from human genital organs by polymerase chain reaction.

Res. Commun. Inst. Ferment. 18:6-12(1997)

 

PubMed=11330945; DOI=10.1006/gyno.2001.6132

Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M., Sato A., Inazawa J.

A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization.

Gynecol. Oncol. 81:172-177(2001)

 

PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x; PMCID=PMC5926887

Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M., Takayama M., Sato A., Inazawa J.

Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.

Jpn. J. Cancer Res. 93:1114-1122(2002)

 

PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567

Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., Inazawa J., Imoto I.

Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.

Cancer Res. 67:7095-7105(2007)

 

PubMed=20081105; DOI=10.1210/me.2009-0295; PMCID=PMC2817607

Nagaraja A.K., Creighton C.J., Yu Z.-F., Zhu H.-F., Gunaratne P.H., Reid J.G., Olokpa E., Itamochi H., Ueno N.T., Hawkins S.M., Anderson M.L., Matzuk M.M.

A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Mol. Endocrinol. 24:447-463(2010)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)